Takeda Pharmaceutical Company Limited announced the appointment of Yasuchika Hasegawa as Director, Chairman of the Board from his previous position Representative Director, Chairman of the Board. The company also appointed Andrew Plump, M.D., Ph.D. as Director, Chief Medical and Scientific Officer from his previous position Corporate Officer and Yasuhiko Yamanaka as Corporate Auditor from his previous position Managing Director.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,130 JPY | -0.19% | +1.47% | +1.87% |
16/05 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
15/05 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.87% | 41.81B | |
+32.01% | 694B | |
+29.39% | 593B | |
-1.57% | 371B | |
+19.91% | 331B | |
+7.16% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.26% | 169B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- Takeda Pharmaceutical Company Limited Announces Executive Appointments